Abstract
Tiotropium Respimat® is a newly developed device which delivered the drug with ease. In this paper we've described the efficacy and patients' satisfaction for two groups of patients, 1; the first users of anti-muscarinic inhelor (33 patients) 2; changed users from Tiotropium Handyhelor® to Respimat® (67 patiens).
Methods: One hundred consequent COPD patients administered Tiotropium Respimat® were enrolled. Eight weeks later, impressions about the devices and pulmonary function tests were recorded. Patients satisfaction was measured by the following, 1) Easily understand how to use the device, 2) time consumption to inhale, 3) irritability of the inhaled drug, 4) easy to mobile the device, 5) adherence. Visual analogue scale from 1 (most negative) to 5 (most positive) were used.
Results: 1) - 1 Patients mean impression score of first users showed rather positive impression, Q1: 3.78, Q2: 3.89, Q3: 4.27, Q4: 4.03, Q5: 3.55. 1) - 2 Patients impression score of the changed users (from Handyhelor® to Respimat®) were significantly improved. Q1: 2.75±0.09 to 3.80±0.08. Q2: 1.32±0.07 to 3.40±0.07, Q3: 2.54±0.07 to 3.68±0.07, Q4: 1.91±0.08 to 3.80±0.08, and Q5: 1.55±0.09 to 3.77±0.08 (p=0.001∼0.0001). 2) Pulmonary function tests of the changed users showed no significant improvement about VC and IC and showed not significant but a little improvement of FEV1 and FEV1% (G) (FEV1; 1.65±0.09 to 1.69±0.09, FEV1% (G); 59.04±2.21 to 60.99±2.40 (%), (p=0.08). Peak expiratory flow was significantly improved after changed the device (4.53±0.35 to 4.77±0.28,p=0.004).
Conclusion: Tiotropium Respimat® was a simple and comfortable device and it may improve the pulmonary function for the patients with COPD.
- © 2011 ERS